J. Brochard , F. Morio , J. Mahe , P. Le Pape , T. Guimard , B. Mahe , M. Leterrier , M. Morrier , F. Raffi , D. Boutoille
{"title":"Ibrutinib, a Bruton's tyrosine kinase inhibitor, a new risk factor for cryptococcosis","authors":"J. Brochard , F. Morio , J. Mahe , P. Le Pape , T. Guimard , B. Mahe , M. Leterrier , M. Morrier , F. Raffi , D. Boutoille","doi":"10.1016/j.medmal.2020.07.005","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><p>Invasive fungal diseases and especially Cryptococcus neoformans infections are increasingly reported in patients with hematological malignancies receiving ibrutinib, a Bruton's tyrosine kinase inhibitor.</p></div><div><h3>Patients and method</h3><p>We reported three additional cases and reviewed 16 previous published cases together with cases from the international pharmacovigilance database.</p></div><div><h3>Results</h3><p>Patients were mainly treated for chronic lymphocytic leukemia. Cryptococcosis mostly occurred during the first six months (66%) and especially the first two months (44%) of treatment. Clinical presentation is often pulmonary (68%) and the outcome is usually favorable despite ibrutinib continuation.</p></div><div><h3>Conclusion</h3><p>Clinicians must be aware of this infection in patients with hematological malignancies on ibrutinib.</p></div>","PeriodicalId":18464,"journal":{"name":"Medecine et maladies infectieuses","volume":"50 8","pages":"Pages 742-745"},"PeriodicalIF":5.0000,"publicationDate":"2020-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.medmal.2020.07.005","citationCount":"7","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medecine et maladies infectieuses","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0399077X20306739","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 7
Abstract
Purpose
Invasive fungal diseases and especially Cryptococcus neoformans infections are increasingly reported in patients with hematological malignancies receiving ibrutinib, a Bruton's tyrosine kinase inhibitor.
Patients and method
We reported three additional cases and reviewed 16 previous published cases together with cases from the international pharmacovigilance database.
Results
Patients were mainly treated for chronic lymphocytic leukemia. Cryptococcosis mostly occurred during the first six months (66%) and especially the first two months (44%) of treatment. Clinical presentation is often pulmonary (68%) and the outcome is usually favorable despite ibrutinib continuation.
Conclusion
Clinicians must be aware of this infection in patients with hematological malignancies on ibrutinib.
期刊介绍:
L''organe d''expression de la Société de Pathologie Infectieuse de Langue Française (SPILF).
Médecine et Maladies Infectieuses is the official publication of the Société de Pathologie Infectieuse de Langue Française (SPILF). Médecine et Maladies Infectieuses is indexed in the major databases: Medline, Web of Science/Clarivate and Scopus. The journal publishes scientific /research articles, general reviews, short communications and letters, in both English and French. The journal welcomes submissions on the various aspects of infectious pathologies and pathogenic agents. Médecine et Maladies Infectieuses focuses on clinical therapeutics, nosocomial infections, biology, prevention, as well as epidemiology and therapeutics.